ABSTRACT
The antiemetic activity, gastric motor activity, and dopamine receptor effects of metoclopramide, dazopride, and sulpiride were assessed to establish if enhancement of gastric motility or antagonism of central dopamine receptors is the predominant action for drug-induced suppression of cisplatin-induced emesis. Emesis produced in dogs by cisplatin is antagonized by metoclopramide and dazopride. The antiemetic actions of metoclopramide and dazopride are associated with their ability to enhance gastric motor activity. Dazopride, unlike metoclopramide, has minimal dopamine receptor antagonist properties. Sulpiride is a potent dopamine receptor antagonist; however, it had no effect on the stomach and was ineffective in suppressing cisplatin-induced emesis.
Subject(s)
Benzamides/pharmacology , Cisplatin/antagonists & inhibitors , Gastrointestinal Motility/drug effects , Metoclopramide/pharmacology , Vomiting/physiopathology , Animals , Benzamides/metabolism , Dogs , Dose-Response Relationship, Drug , Female , Male , Metoclopramide/metabolism , Rats , Rats, Inbred Strains , Receptors, Dopamine/drug effects , Sulpiride/metabolism , Sulpiride/pharmacology , Vomiting/chemically induced , Vomiting/drug therapyABSTRACT
A series of substituted derivatives of 2-amino-3-benzoylphenylacetic acid (amfenac) has been synthesized and evaluated for antiinflammatory, analgesic, and cyclooxygenase inhibiting activity. Several derivatives including 157 (4'-chloro), 158 (4'-bromo), and 182 (5-chloro, 4'-bromo) were more potent than indomethacin in these assays.
Subject(s)
Anti-Inflammatory Agents/chemical synthesis , Phenylacetates/chemical synthesis , Analgesia , Animals , Arthritis, Experimental/drug therapy , Chemical Phenomena , Chemistry , Cyclooxygenase Inhibitors , Female , Indomethacin/therapeutic use , Intestines/drug effects , Isomerism , Male , Phenylacetates/therapeutic use , Phenylacetates/toxicity , Rats , Rats, Inbred Strains , Stomach/drug effectsABSTRACT
The neuropharmacological profile of a series of aminoalkylindole compounds (AHR 1229-(3-[2-(3-indolyl)-ethyl]-butylamino-1-phenyl-pyrrolidine), AHR1771-(1-[2-(2-methyl-3-indolyl)ethyl]-4-phenyl-3,4-dehydropiperidine), AHR1806-(1-[2-(5-chloro-3-indolyl)-ethyl]-4-phenyl-3,4-dehydropiperidine), AHR1858-(1-[2-(3-indolyl)ethyl]-4-(4-fluorophenyl)-1,2,3, 6-tetrahydropyridine), AHR1709-(1-[2-(3-indolyl)ethyl]-4-phenyl-1,2,3,6-tetrahydropyridine) was determined in comparison with the classical neuroleptic agents haloperidol and oxypertine, the latter being of similar indole structure. The indole analogues were shown to antagonize amphetamine-induced toxicity in aggregated mice, to indicate a 'tranquillizing' action but, in contrast to haloperidol and oxypertine, showed weak or no activity in other classical behavioural tests for neuroleptic action, catalepsy induction and stereotypy antagonism. In further contrast to haloperidol or oxypertine, the indole derivatives failed to displace [3H]spiperone in radioligand binding assays and failed to increase prolactin levels. However, similarly to both typical and atypical neuroleptic agents, the indole derivatives were shown to inhibit the behavioural hyperactivity resulting from the intracerebral administration of dopamine into the mesolimbic nucleus accumbens of rat. The dissociation of an ability to antagonize a dopamine action in the mesolimbic system from classical neuroleptic actions involving other cerebral dopamine systems is the most important finding of the present study.
